Northeast Financial Consultants’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $676K | Sell |
5,347
-1,464
| -21% | -$180K | 0.03% | 181 |
|
|
2025
Q1 | $871K | Hold |
6,811
| – | – | 0.04% | 156 |
|
|
2024
Q4 | $900K | Hold |
6,811
| – | – | 0.04% | 161 |
|
|
2024
Q3 | $992K | Buy |
6,811
+1
| +0% | +$145 | 0.04% | 155 |
|
|
2024
Q2 | $935K | Sell |
6,810
-120
| -2% | -$16K | 0.04% | 154 |
|
|
2024
Q1 | $951K | Hold |
6,930
| – | – | 0.05% | 150 |
|
|
2023
Q4 | $941K | Sell |
6,930
-1,297
| -16% | -$158K | 0.05% | 145 |
|
|
2023
Q3 | $1.01M | Hold |
8,227
| – | – | 0.06% | 141 |
|
|
2023
Q2 | $1.04M | Hold |
8,227
| – | – | 0.06% | 139 |
|
|
2023
Q1 | $1.06M | Hold |
8,227
| – | – | 0.07% | 140 |
|
|
2022
Q4 | $1.08M | Buy |
8,227
+61
| +0.7% | +$7.88K | 0.07% | 134 |
|
|
2022
Q3 | $955K | Sell |
8,166
-1,009
| -11% | -$125K | 0.07% | 142 |
|
|
2022
Q2 | $1.08M | Buy |
9,175
+977
| +12% | +$116K | 0.08% | 133 |
|
|
2022
Q1 | $1.07M | Sell |
8,198
-945
| -10% | -$123K | 0.06% | 157 |
|
|
2021
Q4 | $1.4M | Buy |
9,143
+2,600
| +40% | +$403K | 0.08% | 124 |
|
|
2021
Q3 | $1.06M | Buy |
6,543
+350
| +6% | +$58.9K | 0.07% | 157 |
|
|
2021
Q2 | $1.01M | Sell |
6,193
-950
| -13% | -$146K | 0.07% | 158 |
|
|
2021
Q1 | $1.07M | Sell |
7,143
-7
| -0.1% | -$1.11K | 0.08% | 140 |
|
|
2020
Q4 | $1.08M | Hold |
7,150
| – | – | 0.09% | 132 |
|
|
2020
Q3 | $968K | Hold |
7,150
| – | – | 0.09% | 131 |
|
|
2020
Q2 | $977K | Buy |
7,150
+3,425
| +92% | +$437K | 0.09% | 126 |
|
|
2020
Q1 | $401K | Hold |
3,725
| – | – | 0.05% | 177 |
|
|
2019
Q4 | $449K | Hold |
3,725
| – | – | 0.04% | 190 |
|
|
2019
Q3 | $371K | Sell |
3,725
-120
| -3% | -$12.6K | 0.04% | 208 |
|
|
2019
Q2 | $419K | Buy |
3,845
+185
| +5% | +$19.7K | 0.04% | 196 |
|
|
2019
Q1 | $409K | Buy |
+3,660
| New | +$401K | 0.05% | 197 |
|
|
2018
Q4 | – | Sell |
-4,540
| Closed | -$553K | – | 176 |
|
|
2018
Q3 | $553K | Buy |
+4,540
| New | +$535K | 0.15% | 82 |
|
|
2017
Q2 | – | Sell |
-2,100
| Closed | -$205K | – | 145 |
|
|
2017
Q1 | $205K | Sell |
2,100
-1,950
| -48% | -$187K | 0.09% | 141 |
|
|
2016
Q4 | $358K | Sell |
4,050
-1,395
| -26% | -$127K | 0.16% | 106 |
|
|
2016
Q3 | $525K | Sell |
5,445
-5,400
| -50% | -$514K | 0.22% | 77 |
|
|
2016
Q2 | $930K | Buy |
+10,845
| New | +$973K | 0.41% | 42 |
|
|
2015
Q2 | – | Sell |
-11,715
| Closed | -$1.34M | – | 153 |
|
|
2015
Q1 | $1.34M | Buy |
11,715
+5,145
| +78% | +$567K | 0.61% | 35 |
|
|
2014
Q4 | $664K | Hold |
6,570
| – | – | 0.35% | 61 |
|
|
2014
Q3 | $599K | Hold |
6,570
| – | – | 0.33% | 64 |
|
|
2014
Q2 | $562K | Hold |
6,570
| – | – | 0.32% | 60 |
|
|
2014
Q1 | $518K | Buy |
+6,570
| New | +$547K | 0.3% | 67 |
|
Other funds holding IBB
CB
Northeast Financial Consultants's IBB Position: Q2 2025 in Review
Northeast Financial Consultants reduced its iShares Biotechnology ETF (IBB) stake by 21% in Q2 2025, selling an estimated $180K and leaving 5,347 shares worth $676K. The position accounts for 0.03% of the portfolio, ranked #181.
Northeast Financial Consultants first reported a position in IBB in Q1 2014 and has held it in 36 quarters since. The position peaked at $1.4M in Q4 2021. 797 funds tracked by Wall St. Rank hold IBB as of Q2 2025.
- Northeast Financial Consultants held 5,347 shares of iShares Biotechnology ETF worth $676K as of Q2 2025.
- Northeast Financial Consultants sold 1,464 iShares Biotechnology ETF shares in Q2 2025, an estimated $180K.
- iShares Biotechnology ETF made up 0.03% of Northeast Financial Consultants's portfolio in Q2 2025, its #181 holding.
- Northeast Financial Consultants first reported a position in iShares Biotechnology ETF in Q1 2014 and has held it in 36 quarters since.
- Northeast Financial Consultants's iShares Biotechnology ETF position peaked at $1.4M in Q4 2021.
- 797 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2025.
Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.